Full-Life Technologies Breaks Ground for GMP Manufacturing Facility in Belgium to Advance Its End-to-end Solution for Radiopharmaceuticals

December 08, 2023 01:00 PM AEDT | By Cision

Full-Life Technologies Breaks Ground for GMP Manufacturing Facility in Belgium to Advance Its End-to-end Solution for Radiopharmaceuticals — Image source: Kalkine Media

Recent News

Newmont Promotes Natascha Viljoen to President and Chief Operating Off...

Oil prices poised for wild swings as OPEC+ May 5 meeting nears

TSX closes positive on calming trade tensions, strong U.S. jobs report

Stronger jobs report pushes first rate cut bet of 2025 from June to Ju...

GEMBLOUX, Belgium, Dec. 8, 2023 /PRNewswire/ -- Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, today announced the construction of its new Good Manufacturing Practices (GMP) compliant manufacturing facility in Gembloux, Belgium, for radiopharmaceuticals. This strategic investment aims to advance Full-Life's end-to-end solution by enhancing its radiopharmaceutical production capabilities at a key logistical hub to ensure the timely supply and delivery to patients worldwide. The company marked the occasion with a ground-breaking ceremony.

"Today marks a major milestone in Full-Life's evolution to integrated radiopharmaceutical company and highlights our commitment to excellence and innovation in radiotherapeutics," said Philippe van Put, General Manager of Full-Life Technologies Europe. "Effective manufacturing and supply chain management are key to radiopharmaceutical development and commercialization. This facility will ensure a reliable supply for clinical development and Gembloux provides us with a distinct advantage, with its location at the heart of Europe's biotech innovation corridor, its rich pool of professional expertise, and strong logistic network."

Mr. van Put, added, "We want to extend our gratitude to the Walloon Regional Government for their partnership and support in fostering a conducive environment for the radiopharmaceutical industry."

The 4,000 square meter, state-of-the-art facility, which will serve as Full-Life's production hub, integrates sustainable design with automation and digital quality assurance systems. Central to its operations is the commitment to maintaining control and reliability within its supply chain and achieving cost-effectiveness. The facility, which will sit on 17,000 square meters of land, is specifically tailored to produce a broad spectrum of radiopharmaceuticals.

The groundbreaking ceremony brought together industry experts, healthcare professionals, community leaders, and investors, to celebrate Full-Life's groundbreaking project in Gembloux and recognize a milestone in Full-Life's mission.

About Full-Life Technologies

Full-Life Technologies Limited ("Full-Life") is a fully integrated global radiotherapeutics company with operations in Belgium, Germany, and China. We seek to own the entire value chain for radiopharmaceutical research & development, production & commercialization in order to deliver clinical impact for patients. The company plans to attack core issues affecting radiopharmaceuticals today through innovative research that targets the treatments of tomorrow. We are comprised of a team of fast-moving entrepreneurs and scientists with a demonstrated track record in the life sciences, as well as radioisotope research and clinical development.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.